Neoplasms
Astellas Secures $1.34B Licensing Deal for CLDN18.2-Targeted ADC with Evopoint Biosciences
Astellas; Evopoint Biosciences; CLDN18.2; antibody-drug conjugate; ADC; licensing deal; oncology; XNW27011
Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space
Genentech; Orionis Biosciences; molecular glue; oncology; drug discovery; cancer; partnership; biotech; protein degraders; Allo-Glue platform
Pfizer Pays $1.25B Upfront to 3SBio, Joining the PD-1 x VEGF Race with Licensing Deal for SSGJ-707
Pfizer; 3SBio; PD-1/VEGF bispecific antibody; SSGJ-707; oncology; upfront payment; licensing deal; cancer therapy; China; drug development
ASCO25 Primer: Navigating Cancer R&D Amid Regulatory Uncertainty
ASCO25; cancer research; oncology; regulatory uncertainty; immunotherapy; precision medicine; diagnostics; expert perspectives; policy changes
Boehringer Ingelheim Expands Oncology Pipeline via Strategic Collaboration with Tempus AI
Boehringer Ingelheim; Tempus AI; oncology; cancer research; real-world data; AI; biomarker discovery; drug development; strategic collaboration
AbbVie Commits $335M Upfront in Landmark siRNA Deal With ADARx
AbbVie; ADARx Pharmaceuticals; siRNA therapeutics; gene silencing; neuroscience; immunology; oncology; biotech partnerships; RNA technology; drug development
Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures
Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology
Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer
Regeneron, Lynozyfic, Bispecific Antibody, Multiple Myeloma, EU Approval, J&J, Pfizer, Oncology
Roche’s WRN Inhibitor Shows Promising Early Results in MSI-H Tumors at AACR25
Roche, WRN inhibitor, MSI-H tumors, AACR25, cancer research, oncology
Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects
Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%